Citations

Clear

16280 citation(s) found for "Yu, David".

Reevaluating lipoprotein(a) levels and risk of all-cause mortality in the setting of primary prevention: a retrospective cohort study
Sheashaa, Hesham, Ali, Nima Baba , Esfahani, Sogol Attaripour , Bismee, Nadera N. , Ibrahim, Omar , Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Hafez, Abdelrahman , Ibrahim, Ramzi , Simper, David, Reddy, Satyajit , Lester, Steven J., Ayoub, Chadi , Arsanjani, Reza, Awad, Kamal , Pietri, Milagros Pereyra, Mahmoud, Ahmed K , Reddy, Satyajit T, Ayoub, Chadi , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Scalia, Isabel G. , Mahmoud, Ahmed , Ibrahim, Ramzi , Arsanjani, Reza

Mayo Clinic

European Journal of Preventive Cardiology | October 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf700 | PMID 41183493 Get It

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Anderson, Daniela R., Gangaraju, Radhika , Sedhom, Wafik G., Hamulyák, Eva N. , Wang, Tzu‐Fei , O’Dwyer, Kristen M. , Muthiah, Chandrasekar, Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Dinner, Shira, Biemond, Bart J. , Goldberg, Leah, Kapadia, Anjani , Levavi, Hannah , Bar‐Natan, Michal , Hyfte, Grace Van , Bansal, Karan, Gerrits, Anke M., Litzow, Mark R. , Luger, Selina M. , Wolach, Ofir , Shomali, William , Stock, W, O'Dwyer, Kristin , Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Sanfilippo, Kristen , Derkach, Andriy , Biemond, Bart J , Levavi, Hannah , Carrier, Marc , Fulcher, Jill , Litzow, Mark R. , Luskin, Marlise R , Wolach, Ofir , Shomali, William , Zwicker, Jeffrey I , Carney, Brian J. , Derkach, Andriy , Nemirovsky, David , Carrier, Marc , Murthy, Guru Subramanian Guru , Stock, Wendy, Leader, Avi

Mayo Clinic

Blood Advances | October 31, 2025 | Volume: 10 | Issue: 3 | Pages: 593-603

10.1182/bloodadvances.2025017862 | PMID 41170879 Get It

Abstract The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving asparaginase-based induction. We conducted a multicenter retrospective cohort study of patients (aged ≥18 years) with newly diagnosed ALL receiving asparaginase-based induction. The derivation and external validation cohorts included 306 and 94 patients, respectively. Primary outcome was VTE at any site. A cause-specific Cox proportional hazards model stratified by thromboprophylaxis and center was performed to identify VTE risk factors in the derivation cohort. A risk prediction model for VTE at 30 days was derived using variables with P value < .05 in the multivariable model and was tested in the validation cohort. VTE risk factors on multivariable analysis in the derivation cohort included D-dimer ≥1 μg fibrinogen equivalent unit per mL (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.07-6.5) and hemoglobin (HR for each 1 g/dL increment, 1.19; 95% CI, 1.06-1.34) at ALL diagnosis. A VTE risk score based on these variables distinguished between a 4% (95% CI, 0.72-12) and 20% (95% CI, 14-27) 30-day cumulative incidence of VTE in the derivation cohort, with similar findings in the validation cohort (area under the curve, 0.56). The negative predictive value for VTE at 30 days was 96% and 93% in the derivation and validation cohorts, respectively, and the positive predictive value was 20% in both. We derived and validated a model using D-dimer and hemoglobin, which stratifies VTE risk in patients with ALL receiving asparaginase-based induction.
Six-Month Local Control Rates and Immune Responses After Pulsed Electric Field Ablation in Metastatic Cancer
Moreno‐Gonzalez, Alicia , Nafie, Ebtesam , Pastori, Chiara , Mammarappallil, Joseph , Seshaiah, Partha, Plentl, Maria B., Hatton, Beryl A. , Neal, Robert E. , Pritchett, Michael A. , Reisenauer, Janani , Fernández-Bussy, Sebastián , DiBardino, David M. , Pua, Bradley B. , Krimsky, William , Nafie, Ebtesam H O , Reisenauer, Janani S , DiBardino, David , Neal, Robert E

Mayo Clinic

Cancers | October 31, 2025 | Volume: 17 | Issue: 21 | Pages: 3495

10.3390/cancers17213495 | PMID 41228287 Get It

Background: The AFFINITY trial (NCT05890872) is a prospective, non-randomized, open-label, single-arm study evaluating the safety, immunological impact, and preliminary efficacy of Aliya pulsed electric field ablation in patients with solid tumors. Thirty-one patients were enrolled; thirty received lung lesion ablation prior to continuation on standard-of-care treatment. This manuscript reports six-month local control outcomes and immunological response characteristics. Radiological outcomes were assessed using a modified RECIST 1.1, and immunological impact was evaluated via changes in peripheral blood immunocyte populations and detection of immunoglobulins (Ig) to tumor-associated antigens in serum post-ablation. Methods: Twenty-eight patients underwent radiological assessment of ablated lesions at approximately 1-, 3-, and 6-month post-ablation to evaluate local control. Peripheral blood was collected for immune monitoring using flow cytometry and to detect IgG responses to biopsy-specific and tumor-associated antigens. Results: At 6 months, two cohorts emerged: 12 received ablation only, and 16 received ablation plus systemic and/or focal therapies (radiotherapy or second ablation). In the ablation-only group, imaging showed local control in all ablated lesions (8/12 SD, 4/12 PR), suggesting local efficacy without systemic therapy in those patients. Immunophenotyping showed dynamic changes in circulating immune cells, including T and B cell activation. A subset also exhibited modulation of tumor antigen-specific IgG, indicating a systemic humoral response. Conclusions: This analysis provides preliminary evidence that this form of ablation may promote local tumor control and modulate systemic immune function. These findings support the immunogenic potential of this specialized energy and warrant further investigation. Extended 12-month data for the full cohort will be reported in a future manuscript.
SAR Disease-focused Panel: Restaging Rectal Cancer MRI Synoptic Report—User Guide with Imaging Review
Sheedy, Shannon P. , Arya, Supreeta , Chang, Kevin J. , Gollub, Marc J. , Homsi, Maria El , Kim, David H. , Lalani, Tasneem, Lee, Sonia , Weiser, Martin R. , Horvat, Natally , Chang, Kevin J , Gollub, Marc , El Homsi, Maria , Khatri, Gaurav , Kim, David H , Lalani, Tasneem , Nougaret, Stephanie , Rauch, Gaiane M , Wasnik, Ashish P , Weiser, Martin , Horvat, Natally , Baheti, Akshay , Kassam, Zahra , Khatri, Gaurav , Nougaret, Stéphanie , Paroder, Viktoriya , Rauch, Gaiane M.

Mayo Clinic

RadioGraphics | October 30, 2025 | Volume: 45 | Issue: 11 | Pages: No page available

10.1148/rg.250006 | PMID 41166105 Get It

The SAR Colorectal and Anal Cancer Disease-focused Panel rectal cancer MRI restaging report template can be used to clarify common areas of confusion and deliver essential insights to ensure that clinically relevant information is effectively communicated to the treatment team.
Proton Beam vs Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma
Tang, Anthony , Krippaehne, Elise , Roozdar, Pooya, Goetschel, Kaitlin , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl H., Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Wang, Eric W., Olson, Brennan , Patel, Zara , Hwang, Peter H , Adida, Samuel , Donohue, Jack K. , Gago, Guilherme , Almeida, João Paulo , Nayak, Jayakar V. , Patel, Chirag, Pinheiro‐Neto, Carlos , Routman, David M. , Snyderman, Carl H , Gompel, Jamie J. Van , Wilke, Christopher , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 60

10.1001/jamaoto.2025.3816 | PMID 41165699 Get It

Importance Adjuvant radiotherapy can improve locoregional control and survival in patients with olfactory neuroblastoma (ONB), particularly with advanced-stage and histologic-grade disease. Standard radiotherapy treatment is with intensity-modulated radiotherapy (IMRT). Proton beam radiotherapy (PBRT) provides theoretical advantages in greater sparing of dose to uninvolved organs at risk. Objective To investigate if there are differences in the effectiveness and radiation treatment–related adverse events (RTAEs) between adjuvant IMRT and PBRT for patients with ONB. Design, Setting, and Participants This propensity score–matched cohort study included patients with ONB treated between February 2005 and April 2021 with either IMRT or PBRT at 9 academic tertiary care centers in North America. Patients were matched 1:2 based on age, modified Kadish stage, and Hyams grade. Data were analyzed from July 2024 to January 2025. Exposure Adjuvant IMRT or adjuvant PBRT. Main Outcomes and Measures Local recurrence-free survival (RFS), any RFS, and overall survival (OS). RTAEs, ie, grade 2 events or higher based on Common Terminology Criteria for Adverse Events, were recorded for both modalities. Results Of 54 included patients, 27 (50%) were female, and the mean (SD) age was 46.2 (15.4) years. A total of 18 were treated with PBRT and 36 were treated with IMRT. Most patients had modified Kadish stage C disease (33 of 54 [61%]), and 24 patients (44%) had Hyams grade III or IV disease. The RTAE rate was 20% (8 of 40); IMRT had a rate of 21% (6 of 29), and PBRT had a rate of 18% (2 of 11). The difference in the point estimates for 10-year RFS showed a potential clinical benefit favoring IMRT, although the wide confidence interval indicates uncertainty (10-year RFS: IMRT, 63.3%; 95% CI, 44.6-89.8; PBRT, 37.8%; 95% CI, 14.2-100; difference, 25.5 percentage points; 95% CI, −17.6 to 68.6). There were no clinically meaningful differences in 10-year local RFS (IMRT, 75.6%; 95% CI, 59.8-95.4; PBRT, 72.7%; 95% CI, 45.2-100; difference, 2.9 percentage points; 95% CI, −35.9 to 41.7) or 10-year OS (IMRT, 61.8%; 95% CI, 42.8-89.1; PBRT, 57.1%; 95% CI, 24.3-100; difference, 4.7 percentage points; 95% CI, −49.2 to 58.6), although wide confidence intervals indicate considerable uncertainty. Conclusions and Relevance Due to the imprecision of estimates, no definitive conclusions can be made regarding the comparative effectiveness of IMRT vs PBRT for patients with ONB. These preliminary data may inform the design of appropriately powered prospective studies evaluating the efficacy of PBRT vs IMRT in this population.
A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked
Wei, Zhao , Zhang, Tongwu , Hua, Xing , Hoang, Phuc H. , Miraftab, Mona , Saha, Monjoy , McElderry, John, Sang, Jian , Lee, Olivia W. , Hartman, Caleb , Sharma, Sunandini , Colón-Matos, Frank J. , Anyaso‐Samuel, Samuel , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer, Zhong, Xiaoming , Yang, Yang , Leung, Kin Chung, Wong, Maria Pik , Mańczuk, Marta , Shangina, Oxana , Заридзе, Давид , Milosavljević, Saša , Ognjanovic, Simona , Savić, Milan , Gaborieau, Valérie , Brennan, Paul , Edell, Eric S. , Más, Luís , Chen, Chih‐Yi , Chang, I‐Shou , Hsiung, Chao A. , Liu, Geoffrey , Santamaría, Juan Miguel , Mutreja, Karun , Rothman, Nathaniel , Leduc, Charles , Sholl, Lynette M. , Lan, Qing , Yang, Lixing , Shi, Jianxin , Landi, Maria Teresa , Zhao, Wei , McElderry, John P , Khandekar, Azhar , Sharma, Sunandini , Colón-Matos, Frank J , Anyaso-Samuel, Samuel , Wang, Difei , Jones, Kristine , Hutchinson, Amy , Hicks, Belynda , Rosenbaum, Jennifer , Zhong, Xiaoming , Yang, Yang , Pesatori, Angela C , Consonni, Dario , Christiani, David C. , Leung, Kin Chung , Wong, Maria Pik , Manczuk, Marta , Lissowska, Jolanta , Świątkowska, Beata , Mukeria, Anush , Shangina, Oxana , Zaridze, David , Holcatova, Ivana , Mates, Dana , Milosavljevic, Sasa , Ognjanovic, Simona , Savic, Milan , Kontic, Milica , Gaborieau, Valerie , Brennan, Paul , Arrieta, Oscar , Bossé, Yohan , Schabath, Matthew B , Hofman, Paul , Mas, Luis , Yendamuri, Sai S , Chen, Chih-Yi , Chang, I-Shou , Hsiung, Chao Agnes , Liu, Geoffrey , Martinez Santamaría, Jacobo , Gould Rothberg, Bonnie E , Mutreja, Karun , Lawrence, Scott M. , Rothman, Nathaniel , Alexandrov, Ludmil B , Leduc, Charles , Baine, Marina K , Joubert, Philippe , Sholl, Lynette , Travis, William D , Homer, Robert , Lan, Qing , Chanock, Stephen Jacob , Yang, Lixing , Yang, Soo-Ryum , Shi, Jianxin , Landi, Maria T , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Mateș, Dana , Arrieta, Óscar , Bossé, Yohan , Schabath, Matthew B. , Alexandrov, Ludmil B. , Travis, William D. , Homer, Robert

Mayo Clinic

Cancer Discovery | October 30, 2025 | Volume: 16 | Issue: 3 | Pages: 460-477

10.1158/2159-8290.cd-25-0581 | PMID 41165571 Get It

Abstract Understanding tumor cell dynamics can improve prognosis and treatment but remains limited for lung adenocarcinoma in people who have never smoked (NS-LUAD). With RNA sequencing data from 684 NS-LUAD cases and validation in an independent dataset, we identified three subtypes with distinct phenotypic traits and cell compositions. Additional genomic and histologic data further characterized the subtypes. “Steady,” marked by low proliferation, high alveolar cell fraction, moderate-to-well differentiation, and fewer driver gene alterations, is linked to prolonged survival and low immune evasion. “Proliferative” shows high proliferation markers, TP53 mutations, and gene fusions. “Chaotic,” with high epithelial-to-mesenchymal transition markers, has the worst prognosis, even within stage I tumors. Lacking known molecular or histologic characteristics, this aggressive subtype is solely identified by transcriptomic data. A 60-gene signature recapitulates the classification and predicts survival even within subgroups based on tumor stage or known genomic features, emphasizing its potential for improving early-stage NS-LUAD prognostication in clinical settings. Significance: The transcriptome of 684 NS-LUAD identifies three subtypes with different cellular dynamics and genomic and morphologic features. A 60-gene signature accurately stratifies subjects for mortality risk, even in stage I, offering a potential clinically applicable tool for treatment decision-making in patients with NS-LUAD. See related commentary by Azizi et al., p. 423
Lichen planus‐like drug eruption: A disproportionality analysis using FAERS database
Tran, Tung S, Le, Duc V. , Nguyen, Trang M , Lehman, Julia S. , Wetter, David A., Nguyen, Giang Huong , Tran, Tung S. , Tran, Tung S , Nguyen, Giang H , Le, Duc V. , Lehman, Julia S , Nguyen, Trang M , Doanh, Le Huu , Wetter, David A.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | October 30, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1111/jdv.70140 | PMID 41165063 Get It

Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study
Alouani, Emily , Tougeron, David , Roces, Guillaume, Pernot, Simon , Dutherage, Marie, Cohen, Romain , Hafliger, Émilie , Sclafani, Francesco , Masson, Thérèse, Coutzac, Clélia , Mazard, Thibault , Jaffrelot, Marion, Guimbaud, Rosine , Sèlves, Janick , Taieb, Julien , Tougeron, David , Cohen, Romain , Coutzac, Clélia , Taı̈eb, Julien , Hollebecque, Antoine , Parent, Pauline , Sinicrope, Frank A. , Hautefeuille, Vincent , Abdelghani, Méher Ben , Müller, Marie , Perkins, Géraldine , Aparicio, Thomas , Decraecker, Marie

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 30, 2025 | Volume: 13 | Issue: 10 | Pages: e011436

10.1136/jitc-2024-011436 | PMID 41167636 Get It

Background Tumors with mismatch repair deficiency (MMRd) classically display concomitant loss of MLH1/PMS2 or MSH2/MSH6 on immunohistochemistry (IHC) with microsatellite instability-high (MSI-High) status on molecular testing. Nevertheless, a different phenotype can occur in up to 15% of MMRd tumors (unusual phenotype). Data on the efficacy of immunotherapy in this population remain scarce. Methods We conducted a retrospective study within the IMMUNODIG MSI cohort including patients with advanced gastrointestinal MMRd tumors treated with immune checkpoint blockade in the real-world setting. We selected patients with both IHC and MSI assays data available. Unusual MMRd tumors were classified into four distinct groups: (1) isolated loss of PMS2 or MSH6 with MSI-H (isolated/MSI-H), (2) complex loss of MMR proteins with MSI-H (complex/MSI-H), (3) loss of one or more MMR proteins without MSI-H (MMRd-IHC/microsatellite stability (MSS) or MSI-low (MSI-L)), and (4) four MMR proteins retained with MSI-H (retained IHC/MSI-H). Results Out of 759 patients in the IMMUNODIG-MSI cohort, 571 patients met inclusion criteria. Of these, 90 (15.8%) had an unusual phenotype (47 isolated/MSI-H, 19 complex/MSI-H, 16 MMRd-IHC/MSS or MSI-L and 8 retained IHC/MSI-H). Compared with classical phenotypes, patients with a tumor harboring an unusual phenotype had a younger age at treatment (p=0.005), increased RAS mutation (p=0.005), reduced BRAF p.V600E mutation rates (p<0.001), a higher proportion of Lynch syndrome (p<0.001) and a higher prevalence of non-colorectal cancers (p=0.021). After a median follow-up of 28.1 months (mo), there was a significant difference in progression-free survival, with median values of not reached, 66.4 mo, 37.2 mo, 18.3 mo and 5.5 mo for complex/MSI-H, isolated/MSI-H, classical, retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L subgroups, respectively (p<0.001). Notably, objective response rates were 59.1%, 58.7%, and 63.2% for complex/MSI-H, isolated/MSI-H and classical contrasting with 50% and 25% for retained IHC/MSI-H and MMRd-IHC/MSS or MSI-L, with no complete response observed in the latter two. Conclusion Our findings underscore the need for dual testing and advocate for the presence of both MMRd-IHC and MSI-H for optimal immunotherapy response. Of note, complex MMR aberrations and isolated PMS2/MSH6 losses with MSI-H may represent promising candidates for enhanced immunotherapy efficacy.
Developmental Differences in Myocardial Mitochondrial Reticulum Networks in the Offspring Exposed to Diabetic Pregnancy
Ayyappan, Prathapan , Gandy, Tyler C. T., Sturdevant, David , Larsen, Tricia D. , Mukuntharaj, Pradeeksha , Paulson, Andrew, Christensen, Trace , Salisbury, Jeffrey L., Baack, Michelle , Christensen, Trace A , Baack, Michelle L

Mayo Clinic

Cells | October 29, 2025 | Volume: 14 | Issue: 21 | Pages: 1698

10.3390/cells14211698 | PMID 41227343 Get It

Diabetic pregnancy increases the offspring’s risk of neonatal and adult cardiovascular disease (CVD). We previously used a rat model (Sprague–Dawley) to show that diabetic pregnancy impairs mitochondrial bioenergetics, dynamics, mitophagy, and quality control in the offspring’s heart, and we hypothesized that mitochondrial dysfunction during early development influences the adult myocardium structure to confer cardiometabolic disease risk with aging. Here, we used 3D serial block face-scanning electron microscopy (SBF-SEM) to analyze perinuclear (PN) and intrafibrillar (IF) mitochondrial networks in the left ventricular sections from control and pregestational diabetes-exposed newborn (NB) rats that were three-week-old and four-month-old. Diabetes-exposed myocardium had 50% fewer PN and 20% fewer IF mitochondria at birth but counts increased more rapidly, resulting in no difference at three weeks and 35% more PN and 49% more IF mitochondria by four months. Despite rising counts, mitochondria volumes remained significantly lower at every developmental timepoint. This shows that diabetic pregnancy causes maldevelopment of the myocardial mitochondrial reticulum which likely contributes to adult CVD.
Indomethacin Fails to Increase Intestinal Permeability in Healthy Volunteers
Camilleri, Michael , Busciglio, Irene, Carlson, Paula, Lupianez‐Merly, Camille , Yang, David Yi , Ryks, Michael, Ferber, Monique, Houamel, Dounia, Perot, Stéphanie, Montestruc, François , Dilmaghani, Saam , Lupianez-Merly, Camille, Yang, David Y.

Mayo Clinic

Clinical and Translational Gastroenterology | October 28, 2025 | Volume: 17 | Issue: 1 | Pages: e00944

10.14309/ctg.0000000000000944 | PMID 41147830 Get It

INTRODUCTION: Indomethacin is often used experimentally to induce intestinal hyperpermeability, enabling evaluation of interventions targeting barrier function. METHODS: We conducted a randomized, double-blind, placebo-controlled study (NCT05538247) in healthy volunteers to assess whether a supplement could mitigate indomethacin-induced hyperpermeability. Participants received 150 mg/d of indomethacin for 6 days, either before or during placebo/supplement administration. Permeability was measured using 13 C-mannitol and lactulose urinary excretion. RESULTS: Contrary to expectations, indomethacin failed to increase 13 C-mannitol excretion in either group. No meaningful elevations in serum (zonulin, claudins) or fecal (calprotectin) biomarkers were observed. DISCUSSION: Our findings suggest that the expected increase in intestinal permeability after indomethacin administration may not be consistently observed in healthy volunteers. These results highlight the need to carefully consider the reproducibility and sensitivity of this model in future clinical studies aiming to investigate gut barrier function.